Corporate Board Profile
Tech Score: 25/100
1 mention(s) identify SUSAN DESMOND-HELLMANN, M.D., M.P.H. as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| PFIZER INC | 2022-03-17 | Director Nominees: Susan Desmond-Hellmann, M.D., M.P.H. - Technology. | Has experience in technology and innovation from her previous roles, including as a director on public company boards, including Facebook Inc. (now Meta). |
| Filing Date | Source Excerpt |
|---|---|
| 2021-03-12 | Susan Desmond-Hellmann, M.D., M.P.H. AGE: 63 DIRECTOR SINCE: 2020 BOARD COMMITTEES: Governance & Sustainability and Science and Technology Served as the Chief Executive Officer of the Bill & Melinda Gates Foundation, a private foundation committed to enhancing global healthcare, reducing extreme poverty and expanding educational opportunities, from 2014 until her retirement in 2020, and currently continues as a Senior Advisor and a Board member of the Gates Medical Research Institute. Prior to joining the Bill & Melinda Gates Foundation, she served as the first female and ninth overall Chancellor of the University of California, San Francisco (UCSF) from 2009 to 2014. Dr. Desmond-Hellmann remains an Adjunct Professor at UCSF. From 1995 through 2009, Dr. Desmond-Hellmann was employed at Genentech where she served as President of Product Development from 2005-2009, overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, she was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. Director of Facebook Inc. from 2013 to 2019. Director of Procter & Gamble from 2010 to 2017. KEY SKILLS & EXPERIENCE: Business Leadership & Operations: Dr. Desmond-Hellmann brings strong leadership, expertise in business operations and global perspectives to the Board through her experiences as former Chief Executive Officer of the Bill & Melinda Gates Foundation, where she oversaw the creation of the Gates Medical Research Institute and as former President of Product Development at Genentech. Medicine & Science/Healthcare & Pharma/Academia: Dr. Desmond-Hellmann’s background reflects significant achievements in medicine, healthcare and academia. Dr. Desmond-Hellmann brings expertise in medicine and science from her leadership roles in product development and clinical cancer research. Through her experiences at a biotechnology and pharmaceutical institute, she brings healthcare and pharma industry expertise. In addition, she has significant achievements in academia through her service as a distinguished professor at UCSF. Pfizer and the Board benefit from her depth of experience and expertise in medicine, healthcare and academia. Technology: Dr. Desmond-Hellmann brings an expertise in technology and innovation from her experiences at Genentech and as a director on other public company boards, including a public technology company. |
| 2022-03-17 | Director Nominees: Susan Desmond-Hellmann, M.D., M.P.H. - Technology. |
| 2023-03-16 | Susan Desmond-Hellmann, M.D., M.P.H., Age: 65, Director Since: 2020, Board Committees: Governance & Sustainability and Science and Technology, Total Compensation: $355,948 |
| 2024-03-14 | Susan Desmond-Hellmann, M.D., M.P.H. Age: 66 Director Since: 2020 Board Committees: Governance & Sustainability and Science and Technology 2023 Director Compensation Table: Fees Earned or Paid in Cash ($) 155,000, Stock Awards ($) 205,000, All Other Compensation ($) —, Total ($) 360,000 |
Data sourced from SEC filings. Last updated: 2025-07-01